Evaluation of the Effect of a Combination of Plants to Regulate Mood

Inclusion Criteria:

• Woman or man, aged of 18 to 75 years;

• Participant presenting a depressive episode, according to the DSM-5 definition;

• Participant presenting a BDI ≥ 14 and ≤ 28 at the inclusion, corresponding to mildto moderate symptoms;

• Participant with a recent episode of depression (less than 2 years), not managed byantidepressant or psychotherapeutic treatment;

• Participant with a current depressive disorder not requiring, in the investigator'sopinion, the initiation of antidepressant medication;

• Provision of signed and dated informed consent form;

• Stated willingness to comply with all study procedures and availability for theduration of the study;

• French speaker.

Exclusion Criteria:

• Participant with a depressive disorder of another nature or any other mentalpathology (schizophrenia, bipolarity, addiction to alcohol or drugs...);

• Participant at risk of suicide (determined by the Investigator, or HAMD item 3 score > 2) or having made a suicide attempt in the last 5 years;

• Participant with depression for more than 2 years;

• Participant undergoing psychotropic treatment (current or in the month prior toinclusion) (neuroleptic, anxiolytic, hypnotic);

• Participant with a serious health problem for which the Investigator considers thatit is not in the participant's interest to participate in the study;

• Participant using products containing piperine or millpertuis, or having a knowneffect on mood within the last 4 weeks;

• Pregnant or breastfeeding women, or those planning to become pregnant within thenext 8 weeks;

• Participant with an allergy or contraindication to any component of the study drug;

• Participant unable to understand study information (mental or linguisticdisability);

• Participant who is participating or has participated in the previous month inanother clinical trial.